CStone's CS2009 shows 87.5% response rate in first-line PD-L1-high lung cancer

• CStone Pharmaceuticals presented CS2009 data from more than 300 patients at ESMO 2026, showing antitumor activity across multiple solid tumors.
• Monotherapy response rates reached 87.5% in first-line PD-L1-high non-small-cell lung cancer, versus 28% at 30 mg/kg in heavily pretreated disease.
• In pMMR/MSS metastatic colorectal cancer, response rates were 63.6% with first-line XELOX combination therapy, versus 20% with monotherapy in heavily pretreated patients.
• Safety data showed low rates of severe CTLA-4-associated and VEGF-related toxicities.
• Global registrational Phase III trials are in preparation, with multinational pharmaceutical partnership discussions underway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via CNW (Ref. ID: 202610260421CANADANWCANADAPR_C2799) on October 26, 2026, and is solely responsible for the information contained therein.